These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1794174)

  • 21. Langerhans cell histiocytosis and acute leukemia: unusual association in two cases.
    Aricò M; Comelli A; Bossi G; Raiteri E; Piombo M; Egeler RM
    Med Pediatr Oncol; 1993; 21(4):271-3. PubMed ID: 8469222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-existence of Langerhans cell histiocytosis and reticulohistiocytosis with initial presentation of skull lesions: A case report.
    Shen WC; Chang Liao NF; Lin TY; Wu PY
    J Cutan Pathol; 2019 Jan; 46(1):62-66. PubMed ID: 30251332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Re: "Etoposide in the treatment of six children with Langerhans cell histiocytosis (histiocytosis X)" by Viana et al.
    Whitlock JA
    Med Pediatr Oncol; 1993; 21(5):379. PubMed ID: 8492755
    [No Abstract]   [Full Text] [Related]  

  • 24. Langerhans cell histiocytosis.
    Chu T
    Australas J Dermatol; 2001 Nov; 42(4):237-42. PubMed ID: 11903153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis.
    Gadner H; Grois N; Arico M; Broadbent V; Ceci A; Jakobson A; Komp D; Michaelis J; Nicholson S; Pötschger U; Pritchard J; Ladisch S;
    J Pediatr; 2001 May; 138(5):728-34. PubMed ID: 11343051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of secondary leukemia after treatment with etoposide (VP-16) for Langerhans' cell histiocytosis in Italian and Austrian-German populations.
    Haupt R; Fears TR; Heise A; Gadner H; Loiacono G; De Terlizzi M; Tucker MA
    Int J Cancer; 1997 Mar; 71(1):9-13. PubMed ID: 9096658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of children with multiple system Langerhans cell histiocytosis by Japan Langerhans Cell Histiocytosis Study Group Protocol].
    Huang JB; Xue HM; Chen YY; Huang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):146-9. PubMed ID: 23484709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment results of Langerhans cell histiocytosis with LSH II protocol].
    Mottl H; Ganevová M; Radvanská J; Chánová M; Smelhaus V; Kodet R; Mrhalová M; Tichý M
    Cas Lek Cesk; 2005; 144(11):753-5. PubMed ID: 16335702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Langerhans cell histiocytosis in an adult.
    Sayrak H; Doğan B; Harmanyeri Y; Oztek I; Cingil H
    Cancer Lett; 1994 Sep; 84(2):173-6. PubMed ID: 8076373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
    Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
    Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
    Suminoe A; Matsuzaki A; Hattori H; Ishii S; Hara T
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):633-6. PubMed ID: 11902313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Widespread skin-limited adult Langerhans cell histiocytosis: long-term follow-up with good response to interferon alpha.
    Chang SE; Koh GJ; Choi JH; Lee KH; Sung KJ; Moon KC; Koh JK
    Clin Exp Dermatol; 2002 Mar; 27(2):135-7. PubMed ID: 11952707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Langerhans' cell histiocytosis (histiocytosis X): immunophenotype and growth fraction.
    Hage C; Willman CL; Favara BE; Isaacson PG
    Hum Pathol; 1993 Aug; 24(8):840-5. PubMed ID: 7690735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis (LCH).
    Lopes LF; de Camargo B
    Med Pediatr Oncol; 1999 Apr; 32(4):315. PubMed ID: 10102032
    [No Abstract]   [Full Text] [Related]  

  • 35. Cutaneous Langerhans Cell Histiocytosis Responsive to Topical Nitrogen Mustard.
    Bui AN; Puleo AE; Canales AL; Jacobsen ED; LeBoeuf NR
    J Drugs Dermatol; 2020 Aug; 19(8):803-805. PubMed ID: 32845598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy.
    Minkov M
    Expert Opin Pharmacother; 2018 Feb; 19(3):233-242. PubMed ID: 29355432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine A therapy for multisystem langerhans cell histiocytosis.
    Minkov M; Grois N; Broadbent V; Ceci A; Jakobson A; Ladisch S
    Med Pediatr Oncol; 1999 Nov; 33(5):482-5. PubMed ID: 10531573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrent Skin Langerhan Cell Histiocytosis Successfully Treated With Indomethacin Monotherapy.
    Dhir A; Kelly DR; Watts RG; Kutny MA
    J Pediatr Hematol Oncol; 2020 Nov; 42(8):e795-e797. PubMed ID: 30951019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of Langerhans cell histiocytosis in an adult with initial symptoms confined to the skin.
    Wang X; Yang S; Tu P; Li R
    Int J Dermatol; 2010 Mar; 49(3):337-9. PubMed ID: 20465678
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.